{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=16", "query": { "intervention": "fludarabine", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1451, "total_pages": 146, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T16:12:23.478Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06043323", "title": "A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-01-08", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06043323" }, { "nct_id": "NCT06885697", "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma", "Neoplasms", "Stomach Neoplasms", "Pancreatic Neoplasms", "Ovarian Neoplasms", "Lung Neoplasms", "Thymus Neoplasms", "Colonic Neoplasms" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "TNhYP218 CAR T Cells", "type": "BIOLOGICAL" }, { "name": "mesothelin expression testing", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 120, "start_date": "2025-07-08", "completion_date": "2044-06-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06885697" }, { "nct_id": "NCT01666080", "title": "Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Disorders", "Hemoglobinopathies", "Immunodeficiencies" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Stem cell transplant", "type": "BIOLOGICAL" }, { "name": "Keppra", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 30, "start_date": "2012-08", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01666080" }, { "nct_id": "NCT00574496", "title": "Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "mechlorethamine hydrochloride", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "13 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2007-11-13", "completion_date": "2022-08-02", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574496" }, { "nct_id": "NCT00328861", "title": "Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Metastatic Kidney Cancer" ], "interventions": [ { "name": "Natural Killer (NK) Lymphocytes", "type": "DRUG" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2006-05", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2012-11-05", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00328861" }, { "nct_id": "NCT00864227", "title": "Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma", "Leukemia, Myeloid, Acute", "Burkitt Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Hematopoietic Umbilical Cord Blood Stem Cell Transplantation", "type": "BIOLOGICAL" }, { "name": "GVHD prophylaxis", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": 54, "start_date": "2008-12", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2022-12-14", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 16, "location_summary": "Duarte, California • Gainesville, Florida • Tampa, Florida + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00864227" }, { "nct_id": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Acute Leukemia of Ambiguous Lineage", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Chemosensitivity Assay", "type": "OTHER" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Gene Expression Analysis", "type": "GENETIC" }, { "name": "Genetic Variation Analysis", "type": "GENETIC" }, { "name": "In Vitro Sensitivity-Directed Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "OTHER", "GENETIC", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-11", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551718" }, { "nct_id": "NCT03342196", "title": "Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Year to 65 Years" }, "enrollment_count": 40, "start_date": "2018-03-21", "completion_date": "2024-06-12", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03342196" }, { "nct_id": "NCT06859424", "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AML (Acute Myelogenous Leukemia)", "Acute Lymphoid Leukemia (ALL)", "Acute Leukemia (Category)", "MDS (Myelodysplastic Syndrome)", "CML (Chronic Myelogenous Leukemia)", "CLL (Chronic Lymphocytic Leukemia)", "Prolymphocyctic Leukemia", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasm (MPN)", "Lymphoma", "Myelofibrosis" ], "interventions": [ { "name": "Conditioning Regimen A", "type": "DRUG" }, { "name": "Conditioning Regimen B", "type": "DRUG" }, { "name": "Conditioning Regimen C", "type": "DRUG" }, { "name": "Conditioning Regimen D", "type": "DRUG" }, { "name": "Conditioning Regimen E", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "PTCy (50 mg/kg D3, D4)", "type": "DRUG" }, { "name": "PTCy (25 mg/kg D3, D4)", "type": "DRUG" }, { "name": "Post-transplant Tacrolimus", "type": "DRUG" }, { "name": "Post-transplant Mycophenolate mofetil", "type": "DRUG" }, { "name": "Post-transplant Abatacept", "type": "DRUG" }, { "name": "Post-transplant Ruxolitinib", "type": "DRUG" }, { "name": "Supportive Care: Growth Factors", "type": "DRUG" }, { "name": "Supportive Care: Blood Products", "type": "PROCEDURE" }, { "name": "Supportive Care: Infection Prophylaxis", "type": "OTHER" }, { "name": "Supportive Care: Intravenous immune globulin (IVIG)", "type": "OTHER" }, { "name": "Supportive Care: Seizure prophylaxis", "type": "DRUG" }, { "name": "Supportive Care: Monitoring and management of CRS", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "DRUG" }, { "name": "Supportive Care: Lipid elevations", "type": "OTHER" }, { "name": "Study treatment compliance", "type": "OTHER" }, { "name": "Prohibited Concomitant Therapy", "type": "OTHER" }, { "name": "Permitted Concomitant Therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 358, "start_date": "2025-07-25", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06859424" }, { "nct_id": "NCT06066424", "title": "Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Rimiducid", "type": "DRUG" }, { "name": "TROP2-CAR-NK Cells", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2023-10-24", "completion_date": "2040-04-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-25T16:12:23.478Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06066424" } ] }